Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Efficacy and Safety Analysis by Overall Anti-drug Antibody Result up to Week 30 in Patients with Rheumatoid Arthritis Treated with SB2 (an Infliximab Biosimilar) or Reference Infliximab in a Phase III Study Choe, J., Smolen, J., Keystone, E., Genovese, M., Lee, Y., Rho, Y., Therrien, F. J RHEUMATOL PUBL CO. 2017: 872
View details for Web of Science ID 000404641800071